Rezulin was a drug used for the treatment of Type II Diabetes. Parke Davis (a division of Pfzier) fast-tracked Rezulin onto the market in 1997 and represented to doctors that the drug was extremely safe with “side effects comparable to placebo.” In reality, the drug caused severe liver toxicity in some users and was removed from the market in March of 2000.

Littlepage Booth led the state court charge against Parke Davis. The Littlepage Booth team completed over 100 days of depositions of corporate representatives and experts and proved that the drug company ignored clear signals of Rezulin’s liver toxicity, manipulated the FDA into approving this drug and deliberately misled physicians. This company put profits first and consumer safety a distant second.